Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 13;10(9):1516.
doi: 10.3390/vaccines10091516.

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications

Olga Vladimirovna Orlova  1 , Dina Viktorovna Glazkova  1 , Elena Vladimirovna Bogoslovskaya  1 , German Alexandrovich Shipulin  1 , Sergey Mikhailovich Yudin  1
Affiliations
Review

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications

Olga Vladimirovna Orlova et al. Vaccines (Basel). .

Abstract

Modified vaccinia virus Ankara (MVA) is a promising viral vector for vaccine development. MVA is well studied and has been widely used for vaccination against smallpox in Germany. This review describes the history of the origin of the virus and its properties as a vaccine, including a high safety profile. In recent years, MVA has found its place as a vector for the creation of vaccines against various diseases. To date, a large number of vaccine candidates based on the MVA vector have already been developed, many of which have been tested in preclinical and clinical studies. We discuss data on the immunogenicity and efficacy of some of these vaccines.

Keywords: clinical trial; poxvirus; smallpox vaccine; vaccine development; viral vector vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Generation of MVA strain from CVA strain. Location of the major deletion sites.
See this image and copyright information in PMC

References

    1. Fenner F., Henderson D.A., Arita I., Jezek Z., Ladnyi I.D. Smallpox and Its Erradication. World Health Organization; Geneva, Switzerland: 1988. pp. 1–1460.
    1. Sánchez-Sampedro L., Perdiguero B., Mejías-Pérez E., García-Arriaza J., Di Pilato M., Esteban M. The evolution of pox-virus vaccines. Viruses. 2015;7:1726–1803. doi: 10.3390/v7041726. - DOI - PMC - PubMed
    1. Kaynarcalidan O., Mascaraque S.M., Drexler I. Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design. Biomedicines. 2021;9:1780. doi: 10.3390/biomedicines9121780. - DOI - PMC - PubMed
    1. Orenstein W., Offit P., Edwards K.M., Plotkin S. Plotkin’s Vaccines. 7th ed. Elsevier; Amsterdam, The Netherlands: 2017.
    1. Belongia E.A., Naleway A.L. Smallpox Vaccine: The Good, the Bad, and the Ugly. Clin. Med. Res. 2003;1:87–92. doi: 10.3121/cmr.1.2.87. - DOI - PMC - PubMed

LinkOut - more resources